97 related articles for article (PubMed ID: 23973712)
1. Extracellular lipid metabolism influences the survival of ovarian cancer cells.
Kuwata S; Ohkubo K; Kumamoto S; Yamaguchi N; Izuka N; Murota K; Tsujiuchi T; Iwamori M; Fukushima N
Biochem Biophys Res Commun; 2013 Sep; 439(2):280-4. PubMed ID: 23973712
[TBL] [Abstract][Full Text] [Related]
2. The human lipid phosphate phosphatase-3 decreases the growth, survival, and tumorigenesis of ovarian cancer cells: validation of the lysophosphatidic acid signaling cascade as a target for therapy in ovarian cancer.
Tanyi JL; Morris AJ; Wolf JK; Fang X; Hasegawa Y; Lapushin R; Auersperg N; Sigal YJ; Newman RA; Felix EA; Atkinson EN; Mills GB
Cancer Res; 2003 Mar; 63(5):1073-82. PubMed ID: 12615725
[TBL] [Abstract][Full Text] [Related]
3. Role of decreased levels of lipid phosphate phosphatase-1 in accumulation of lysophosphatidic acid in ovarian cancer.
Tanyi JL; Hasegawa Y; Lapushin R; Morris AJ; Wolf JK; Berchuck A; Lu K; Smith DI; Kalli K; Hartmann LC; McCune K; Fishman D; Broaddus R; Cheng KW; Atkinson EN; Yamal JM; Bast RC; Felix EA; Newman RA; Mills GB
Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3534-45. PubMed ID: 14506139
[TBL] [Abstract][Full Text] [Related]
4. Characterization of an ovarian cancer activating factor in ascites from ovarian cancer patients.
Xu Y; Gaudette DC; Boynton JD; Frankel A; Fang XJ; Sharma A; Hurteau J; Casey G; Goodbody A; Mellors A
Clin Cancer Res; 1995 Oct; 1(10):1223-32. PubMed ID: 9815916
[TBL] [Abstract][Full Text] [Related]
5. A gonadotropin-releasing hormone-responsive phosphatase hydrolyses lysophosphatidic acid within the plasma membrane of ovarian cancer cells.
Imai A; Furui T; Tamaya T; Mills GB
J Clin Endocrinol Metab; 2000 Sep; 85(9):3370-5. PubMed ID: 10999836
[TBL] [Abstract][Full Text] [Related]
6. Roles of LPA in ovarian cancer development and progression.
Pua TL; Wang FQ; Fishman DA
Future Oncol; 2009 Dec; 5(10):1659-73. PubMed ID: 20001802
[TBL] [Abstract][Full Text] [Related]
7. Lysophosphatidic acid is a major regulator of growth-regulated oncogene alpha in ovarian cancer.
Lee Z; Swaby RF; Liang Y; Yu S; Liu S; Lu KH; Bast RC; Mills GB; Fang X
Cancer Res; 2006 Mar; 66(5):2740-8. PubMed ID: 16510595
[TBL] [Abstract][Full Text] [Related]
8. Lysophosphatidic acid activates lipogenic pathways and de novo lipid synthesis in ovarian cancer cells.
Mukherjee A; Wu J; Barbour S; Fang X
J Biol Chem; 2012 Jul; 287(30):24990-5000. PubMed ID: 22665482
[TBL] [Abstract][Full Text] [Related]
9. Fatty acid composition of lysophosphatidic acid and lysophosphatidylinositol in plasma from patients with ovarian cancer and other gynecological diseases.
Shen Z; Wu M; Elson P; Kennedy AW; Belinson J; Casey G; Xu Y
Gynecol Oncol; 2001 Oct; 83(1):25-30. PubMed ID: 11585410
[TBL] [Abstract][Full Text] [Related]
10. Lysophosphatidic acid is constitutively produced by human peritoneal mesothelial cells and enhances adhesion, migration, and invasion of ovarian cancer cells.
Ren J; Xiao YJ; Singh LS; Zhao X; Zhao Z; Feng L; Rose TM; Prestwich GD; Xu Y
Cancer Res; 2006 Mar; 66(6):3006-14. PubMed ID: 16540649
[TBL] [Abstract][Full Text] [Related]
11. Cell type-selective pathways and clinical associations of lysophosphatidic acid biosynthesis and signaling in the ovarian cancer microenvironment.
Reinartz S; Lieber S; Pesek J; Brandt DT; Asafova A; Finkernagel F; Watzer B; Nockher WA; Nist A; Stiewe T; Jansen JM; Wagner U; Konzer A; Graumann J; Grosse R; Worzfeld T; Müller-Brüsselbach S; Müller R
Mol Oncol; 2019 Feb; 13(2):185-201. PubMed ID: 30353652
[TBL] [Abstract][Full Text] [Related]
12. [Lysophosphatidic acid as a potential target for treatment and molecular diagnosis of epithelial ovarian cancers].
Tanyi J; Rigó J
Orv Hetil; 2009 Jun; 150(24):1109-18. PubMed ID: 19739275
[TBL] [Abstract][Full Text] [Related]
13. [Expression of lysophosphatidic acid receptor in human ovarian cancer cell lines 3AO, SKOV3, OVCAR3 and its significance].
Wang P; Wu XH; Chen WX; Shan BE; Guo Q
Di Yi Jun Yi Da Xue Xue Bao; 2005 Nov; 25(11):1422-4, 1431. PubMed ID: 16305971
[TBL] [Abstract][Full Text] [Related]
14. Lysophosphatidic Acid Up-Regulates Hexokinase II and Glycolysis to Promote Proliferation of Ovarian Cancer Cells.
Mukherjee A; Ma Y; Yuan F; Gong Y; Fang Z; Mohamed EM; Berrios E; Shao H; Fang X
Neoplasia; 2015 Sep; 17(9):723-734. PubMed ID: 26476080
[TBL] [Abstract][Full Text] [Related]
15. Hypoxia enhances lysophosphatidic acid responsiveness in ovarian cancer cells and lysophosphatidic acid induces ovarian tumor metastasis in vivo.
Kim KS; Sengupta S; Berk M; Kwak YG; Escobar PF; Belinson J; Mok SC; Xu Y
Cancer Res; 2006 Aug; 66(16):7983-90. PubMed ID: 16912173
[TBL] [Abstract][Full Text] [Related]
16. Aberrant expression of JNK-associated leucine-zipper protein, JLP, promotes accelerated growth of ovarian cancer.
Ha JH; Yan M; Gomathinayagam R; Jayaraman M; Husain S; Liu J; Mukherjee P; Reddy EP; Song YS; Dhanasekaran DN
Oncotarget; 2016 Nov; 7(45):72845-72859. PubMed ID: 27655714
[TBL] [Abstract][Full Text] [Related]
17. Lysophosphatidic acid downregulates tissue inhibitor of metalloproteinases, which are negatively involved in lysophosphatidic acid-induced cell invasion.
Sengupta S; Kim KS; Berk MP; Oates R; Escobar P; Belinson J; Li W; Lindner DJ; Williams B; Xu Y
Oncogene; 2007 May; 26(20):2894-901. PubMed ID: 17130843
[TBL] [Abstract][Full Text] [Related]
18. Heparin-binding EGF-like growth factor is a promising target for ovarian cancer therapy.
Miyamoto S; Hirata M; Yamazaki A; Kageyama T; Hasuwa H; Mizushima H; Tanaka Y; Yagi H; Sonoda K; Kai M; Kanoh H; Nakano H; Mekada E
Cancer Res; 2004 Aug; 64(16):5720-7. PubMed ID: 15313912
[TBL] [Abstract][Full Text] [Related]
19. Cyclooxygenase-2 functions as a downstream mediator of lysophosphatidic acid to promote aggressive behavior in ovarian carcinoma cells.
Symowicz J; Adley BP; Woo MM; Auersperg N; Hudson LG; Stack MS
Cancer Res; 2005 Mar; 65(6):2234-42. PubMed ID: 15781636
[TBL] [Abstract][Full Text] [Related]
20. Constitutive and lysophosphatidic acid (LPA)-induced LPA production: role of phospholipase D and phospholipase A2.
Eder AM; Sasagawa T; Mao M; Aoki J; Mills GB
Clin Cancer Res; 2000 Jun; 6(6):2482-91. PubMed ID: 10873103
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
